The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Longitudinal tau PET in ageing and Alzheimer’s disease
Open accessAbstract
See Hansson and Mormino (doi:10.1093/brain/awy065) for a scientific commentary on this article.Our objective was to compare different whole-brain and region-specific measurements of within-person change on serial tau PET and evaluate its utility for clinical trials. We studied 126 individuals: 59 cognitively unimpaired with normal amyloid, 37 cognitively unimpaired with abnormal amyloid, and 30 cognitively impaired with an amnestic phenotype and abnormal amyloid. All had baseline amyloid PET and two tau PET, MRI, and clinical assessments. We compared the topography across all cortical regions of interest of tau PET accumulation rates and the rates of four different whole-brain or region-specific meta-regions of interest among the three clinical groups. We computed sample size estimates for change in tau PET, cortical volume, and memory/mental status indices for use as outcome measures in clinical trials. The cognitively unimpaired normal amyloid group had no observable tau accumulation throughout the brain. Tau accumulation rates in cognitively unimpaired abnormal amyloid were low [0.006 standardized uptake value ratio (SUVR), 0.5%, per year] but greater than rates in the cognitively unimpaired normal amyloid group in the basal and mid-temporal, retrosplenial, posterior cingulate, and entorhinal regions of interest. Thus, the earliest elevation in accumulation rates was widespread and not confined to the entorhinal cortex. Tau accumulation rates in the cognitively impaired abnormal amyloid group were 0.053 SUVR (3%) per year and greater than rates in cognitively unimpaired abnormal amyloid in all cortical areas except medial temporal. Rates of accumulation in the four meta-regions of interest differed but only slightly from one another. Among all tau PET meta-regions of interest, sample size estimates were smallest for a temporal lobe composite within cognitively unimpaired abnormal amyloid and for the late Alzheimer's disease meta-region of interest within cognitively impaired abnormal amyloid. The ordering of the sample size estimates by outcome measure was MRI < tau PET < cognitive measures. At a group-wise level, observable rates of short-term serial tau accumulation were only seen in the presence of abnormal amyloid. As disease progressed to clinically symptomatic stages (cognitively impaired abnormal amyloid), observable rates of tau accumulation were seen uniformly throughout the brain providing evidence that tau does not accumulate in one area at a time or in start-stop, stepwise sequence. The information captured by rate measures in different meta-regions of interest, even those with little topographic overlap, was similar. The implication is that rate measurements from simple meta-regions of interest, without the need for Braak-like staging, may be sufficient to capture progressive within-person accumulation of pathologic tau. Tau PET SUVR measures should be an efficient outcome measure in disease-modifying clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Longitudinal deposition in tau PET is associated with baseline levels tau and Aβ deposition is a necessary antecedent for spread of tau beyond the temporal lobe in AD [189, 190] (Fig. 3).”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Brain imaging has helped to improve the biological classification of AD by allowing proposed classifications based on pathology, like the ATN staging, to be applied in vivo and opened a new window of therapeutic intervention at preclinical stages.”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [189]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Longitudinal deposition in tau PET is associated with baseline levels tau and Aβ deposition is a necessary antecedent for spread of tau beyond the temporal lobe in AD [189, 190] (Fig. 3).”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [189]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Such imaging has also improved our understanding of the role of mixed pathologies in dementia [102, 175, 189, 247].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [189]
Experimental — accuracy not yet measuredIn the citing paper
“In contrast, cross-sectional and longitudinal human cohort studies of biomarkers support a scenario in which amyloid pathology (Aβ42 lowering in CSF, positive amyloid PET imaging) precedes tau pathology (tau-PET and phospho-Tau elevation in CSF) and then neurodegeneration 126-128 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [127]
In the citing paper
“Antemortem diagnosis also relies heavily on the presence of Aβ and tau, either as measured in the spinal fluid or imaged using positron emission tomography (PET) [7–10].”
From Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau (2021) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Elements of Statistical Learning
Hastie, T., Tibshirani, R., & Friedman, J. (2009) · Springer Series in Statistics · doi:10.1007/978-0-387-84858-7 · Cited by 25,970
The Elements of Statistical Learning
Hastie, T., Friedman, J., & Tibshirani, R. (2001) · Springer Series in Statistics · doi:10.1007/978-0-387-21606-5 · Cited by 24,162
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 2×
“However, that fact that elevated rates in CU A + relative to CU A were not confined to the entorhinal cortex suggests that early tau accumulation may not be as spatially restricted as implied in Braak staging (Braak and Braak, 1991).”
BackgroundResultMild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Propagation of Tau Pathology in a Model of Early Alzheimer's Disease
de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.11.033 · Cited by 1,427
Flagged first, then by citations
Research works printed but not linked: 3
- Bejanin, Do neurodegeneration or amyloid pathology contribute to the relationship between AV-1451 and cognitive symptoms in Alzhimer's disease?, 252
- La Joie, Relationships between AV1451-PET and CSF biomarkers in a heterogeneous clinical sample, 258
- Lowe, 2018, Widespread brain Tau and its association with aging, braak stage, and Alzheimer’s dementia, Brain, 147, 271, 10.1093/brain/awx320 · DOI
Cited by
Sorted by citations
Items 101–200 of 442
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
Ossenkoppele, R., & Hansson, O. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12356 · Cited by 62
Knopman, D. S., Lundt, E. S., Therneau, T. M., Albertson, S. M., Gunter, J. L., Senjem, M. L., Schwarz, C. G., Mielke, M. M., Machulda, M. M., Boeve, B. F., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3921 · Cited by 61
Self-citationDevelopment and validation of a high‐sensitivity assay for measuring p217+tau in plasma
Triana‐Baltzer, G., Moughadam, S., Slemmon, R., Kolen, K. V., Theunis, C., Mercken, M. H., & Kolb, H. C. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12204 · Cited by 63
Franzmeier, N., Dehsarvi, A., Steward, A., Biel, D., Dewenter, A., Roemer, S. N., Wagner, F., Groß, M., Brendel, M., Moscoso, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44374-w · Cited by 63
Secondary prevention of Alzheimer’s dementia: neuroimaging contributions
ten Kate, M., Ingala, S., Schwarz, A. J., Fox, N. C., Chételat, G., van Berckel, B. N. M., Ewers, M., Foley, C., Gispert, J. D., Hill, D., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0438-z · Cited by 65
Sanchez, J. S., Hanseeuw, B. J., Lopera, F., Sperling, R. A., Baena, A., Bocanegra, Y., Aguillon, D., Guzmán-Vélez, E., Pardilla-Delgado, E., Ramirez-Gomez, L., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00765-5 · Cited by 58
Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks
Schumacher, J., Gunter, J. L., Przybelski, S. A., Jones, D. T., Graff‐Radford, J., Savica, R., Schwarz, C. G., Senjem, M. L., Jack, C. R., Lowe, V. J., et al. (2021) · Brain · doi:10.1093/brain/awab218 · Cited by 57
Self-citationFranzmeier, N., Ossenkoppele, R., Brendel, M., Rubinski, A., Smith, R. A., Kumar, A., Mattsson, N., Strandberg, O. T., Duering, M., Büerger, K., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12371 · Cited by 56
Age-related and amyloid-beta-independent tau deposition and its downstream effects
Wuestefeld, A., Binette, A. P., Berron, D., Spotorno, N., van Westen, D., Stomrud, E., Mattsson, N., Strandberg, O. T., Smith, R. A., Palmqvist, S., et al. (2023) · Brain · doi:10.1093/brain/awad135 · Cited by 58
Zou, J., Tao, S., Johnson, A. S., Tomljanovic, Z., Polly, K., Klein, J., Razlighi, Q. R., Brickman, A. M., Lee, S., Stern, Y., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.09.019 · Cited by 55
Kocagöncü, E., Quinn, A. J., Firouzian, A., Cooper, E., Greve, A., Gunn, R. N., Green, G. G. R., Woolrich, M. W., Henson, R. N., Lovestone, S., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.009 · Cited by 55
Alzheimer’s Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology
Agarwal, M., Alam, R., Haider, M. K., Malik, M. Z., & Kim, D.-K. (2020) · Nanomaterials · doi:10.3390/nano11010059 · Cited by 59
Bischof, G. N., Dodich, A., Boccardi, M., van Eimeren, T., Festari, C., Barthel, H., Hansson, O., Nordberg, A. K., Ossenkoppele, R., Sabri, O., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05156-4 · Cited by 54
The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau
Courade, J., Zetterberg, H., Höglinger, G. U., & Dewachter, I. (2025) · Cell · doi:10.1016/j.cell.2025.11.033 · Cited by 57
Drzezga, A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.206300 · Cited by 52
Liu, P., Smith, B. R., Montonye, M. L., Kemper, L. J., Leinonen-Wright, K., Nelson, K. M., Higgins, L., Guerrero, C. R., Markowski, T. W., Zhao, X., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60777-x · Cited by 51
Self-citationWang, Y., Therriault, J., Servaes, S., Tissot, C., Rahmouni, N., Macedo, A. C., Arias, J. F., Mathotaarachchi, S. S., Benedet, A. L., Stevenson, J., et al. (2023) · Brain · doi:10.1093/brain/awad397 · Cited by 54
Self-citationKumar, R., Waisberg, E., Ong, J., Paladugu, P., Amiri, D., Saintyl, J., Yelamanchi, J., Nahouraii, R., Jagadeesan, R., & Tavakkoli, A. (2024) · Brain Sciences · doi:10.3390/brainsci14121266 · Cited by 52
Moscoso, A., Karikari, T. K., Grothe, M. J., Ashton, N. J., Lantero‐Rodriguez, J., Snellman, A., Zetterberg, H., Blennow, K., & Schöll, M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12570 · Cited by 50
Bollack, A., Pemberton, H., Collij, L. E., Markiewicz, P. J., Cash, D. M., Farrar, G., & Barkhof, F. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13158 · Cited by 51
Naude, J., Wang, M., Leon, R., Smith, E. E., & Ismail, Z. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.02.006 · Cited by 49
Association of amyloid-β CSF/PET discordance and tau load 5 years later
Reimand, J., Collij, L. E., Scheltens, P., Bouwman, F. H., Ossenkoppele, R., & Initiative, A. D. N. (2020) · Neurology · doi:10.1212/wnl.0000000000010739 · Cited by 50
Abnormal tau in amyloid PET negative individuals
Yoon, B., Guo, T., Provost, K., Korman, D., Ward, T. J., Landau, S. M., & Jagust, W. J. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.09.019 · Cited by 52
Vanderlinden, G., Ceccarini, J., Vande Casteele, T., Michiels, L., Lemmens, R., Triau, E., Serdons, K., Tournoy, J., Koole, M., Vandenbulcke, M., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01672-x · Cited by 47
White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline
Vemuri, P., Graff‐Radford, J., Lesnick, T. G., Przybelski, S. A., Reid, R. I., Reddy, A. L., Lowe, V. J., Mielke, M. M., Machulda, M. M., Petersen, R. C., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab076 · Cited by 49
Self-citationZhang, L., Du, X., Su, Y., Niu, S., Li, Y., Liang, X., & Luo, H. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01111-z · Cited by 47
Day, G. S. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001089 · Cited by 47
Model-based whole-brain perturbational landscape of neurodegenerative diseases
Perl, Y. S., Fittipaldi, S., Campo, C. G., Moguilner, S., Cruzat, J., Fraile-Vazquez, M. E., Herzog, R. A., Kringelbach, M. L., Deco, G., Prado, P., et al. (2023) · eLife · doi:10.7554/elife.83970 · Cited by 47
Wolters, E. E., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Hansson, O., Nordberg, A. K., Frisoni, G. B., Garibotto, V., & Ossenkoppele, R. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05118-w · Cited by 48
Cross-sectional associations between [18F]GTP1 tau PET and cognition in Alzheimer's disease
Teng, E., Ward, M. E., Manser, P. T., Bohorquez, S. M. S., Ray, R. D., Wildsmith, K. R., Baker, S. L., Kerchner, G. A., & Weimer, R. M. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.05.026 · Cited by 45
Young, C. B., Landau, S. M., Harrison, T. M., Poston, K. L., & Mormino, E. C. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118553 · Cited by 46
Adewale, Q., Khan, A. F., Carbonell, F., Iturria-Medina, Y., & Initiative, A. D. N. (2021) · eLife · doi:10.7554/elife.62589 · Cited by 44
Scott, M. R., Hampton, O. L., Buckley, R. F., Chhatwal, J. P., Hanseeuw, B. J., Jacobs, H. I. L., Properzi, M. J., Sanchez, J. S., Johnson, K. A., Sperling, R. A., et al. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.116991 · Cited by 45
APOEε4 potentiates amyloid β effects on longitudinal tau pathology
Ferrari-Souza, J. P., Bellaver, B., Ferreira, P. C. L., Benedet, A. L., Povala, G., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Soares, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00490-2 · Cited by 43
Wolters, E. E., Ossenkoppele, R., Verfaillie, S. C. J., Coomans, E. M., Timmers, T., Visser, D., Tuncel, H., Golla, S. S. V., Windhorst, A. D., Boellaard, R., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04758-2 · Cited by 45
Neurophysiological and Brain Structural Markers of Cognitive Frailty Differ from Alzheimer's Disease
Kocagöncü, E., Nesbitt, D., Emery, T., Hughes, L. E., Henson, R. N., Cam-CAN, & Rowe, J. B. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.0697-21.2021 · Cited by 45
BACE1 Inhibitors for Alzheimer’s Disease: Current Challenges and Future Perspectives
Coimbra, J. R. M., Resende, R., Custódio, J. B. A., Salvador, J. A. R., & Santos, A. E. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240146 · Cited by 43
MRI-Driven PET Image Optimization for Neurological Applications
Zhu, Y., & Zhu, X. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00782 · Cited by 42
Network Diffusion Modeling Explains Longitudinal Tau PET Data
Schäfer, A., Mormino, E. C., & Ellen Kuhl, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.566876 · Cited by 42
Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly
Carvalho, D. Z., Louis, E. K. S., Schwarz, C. G., Lowe, V. J., Boeve, B. F., Przybelski, S. A., Reddy, A., Mielke, M. M., Knopman, D. S., Petersen, R. C., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009315 · Cited by 41
Self-citationSchwarz, C. G., Therneau, T. M., Weigand, S. D., Gunter, J. L., Lowe, V. J., Przybelski, S. A., Senjem, M. L., Botha, H., Vemuri, P., Kantarci, K., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118259 · Cited by 42
Self-citationKrishnadas, N., Doré, V., Robertson, J. S., Ward, L. D., Fowler, C. J., Masters, C. L., Bourgeat, P., Fripp, J., Villemagne, V. L., & Rowe, C. C. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104450 · Cited by 41
Zhang, J., Chen, H., Wang, J., Huang, Q., Xu, X., Wang, W., Xu, W. L., Guan, Y., Liu, J., Wardlaw, J. M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13845 · Cited by 40
Frank, B. E., Ally, M., Brekke, B., Zetterberg, H., Blennow, K., Sugarman, M. A., Ashton, N. J., Karikari, T. K., Tripodis, Y., Martin, B. M., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12508 · Cited by 40
Giorgio, J., Jagust, W. J., Baker, S. L., Landau, S. M., Peter Tiňo, B., Kourtzi, Z., & Initiative, A. D. N. (2022) · Nature Communications · doi:10.1038/s41467-022-28795-7 · Cited by 40
Tau positron emission tomography in preclinical Alzheimer’s disease
Insel, P. S., Young, C. B., Aisen, P. S. S., Johnson, K. A., Sperling, R. A., Mormino, E. C., & Donohue, M. (2022) · Brain · doi:10.1093/brain/awac299 · Cited by 41
Leuzy, A., Binette, A. P., Vogel, J. W., Klein, G., Borroni, E., Tonietto, M., Strandberg, O. T., Mattsson, N., Palmqvist, S., Pontecorvo, M. J., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.1067 · Cited by 43
Self-citationFunctional network segregation is associated with attenuated tau spreading in Alzheimer's disease
Steward, A., Biel, D., Brendel, M., Dewenter, A., Roemer, S., Rubinski, A., Luan, Y., Dichgans, M., Ewers, M., Franzmeier, N., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12867 · Cited by 39
Rubinski, A., Franzmeier, N., Dewenter, A., Luan, Y., Smith, R. A., Strandberg, O. T., Ossenkoppele, R., Dichgans, M., Hansson, O., Ewers, M., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01074-9 · Cited by 41
Rubinski, A., Tosun, D., Franzmeier, N., Neitzel, J., Frontzkowski, L. K., Weiner, M. W., & Ewers, M. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.02.003 · Cited by 38
Bayesian Physics-Based Modeling of Tau Propagation in Alzheimer's Disease
Schäfer, A., Peirlinck, M., Linka, K., Ellen Kuhl, A., & (ADNI), T. A. D. N. I. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.702975 · Cited by 38
Causal links among amyloid, tau, and neurodegeneration
Bilgel, M., Wong, D. F., Moghekar, A., Ferrucci, L., Resnick, S. M., & Initiative, T. A. D. N. (2022) · Brain Communications · doi:10.1093/braincomms/fcac193 · Cited by 38
Ahmed, M., Chen, J., Arani, A., Senjem, M. L., Cogswell, P. M., Jack, C. R., & Liu, C. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.120357 · Cited by 36
Self-citationWoo, M. S., Tissot, C., Lantero‐Rodriguez, J., Snellman, A., Therriault, J., Rahmouni, N., Macedo, A. C., Servaes, S., Wang, Y., Arias, J. F., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13528 · Cited by 37
Temporal trajectories of in vivo tau and amyloid-β accumulation in Alzheimer’s disease
Baek, M. S., Cho, H., Lee, H. S., Choi, J. Y., Lee, J., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04773-3 · Cited by 37
Hammes, J., Bischof, G. N., Bohn, K. P., Onur, O. A., Schneider, A., Fließbach, K., Hoenig, M. C., Jessen, F., Neumaier, B., Drzezga, A. E., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.244061 · Cited by 37
Relationships between β-amyloid and tau in an elderly population: An accelerated failure time model
Therneau, T. M., Knopman, D. S., Lowe, V. J., Botha, H., Graff‐Radford, J., Jones, D. T., Vemuri, P., Mielke, M. M., Schwarz, C. G., Senjem, M. L., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118440 · Cited by 36
Self-citationvan Weering, J. R. T., & Scheper, W. (2019) · CNS Drugs · doi:10.1007/s40263-019-00643-1 · Cited by 38
What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies
Villemagne, V. L., Lopresti, B. J., Doré, V., Tudorascu, D., Ikonomović, M. D., Burnham, S. C., Minhas, D. S., Pascoal, T. A., Mason, N. S., Snitz, B. E., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.245423 · Cited by 37
Gessi, S., Poloni, T. E., Negro, G., Varani, K., Pasquini, S., Vincenzi, F., Borea, P. A., & Merighi, S. (2021) · Cells · doi:10.3390/cells10092344 · Cited by 36
Visit-to-Visit Blood Pressure Variability and Longitudinal Tau Accumulation in Older Adults
Sible, I. J., Nation, D. A., Weiner, M. W., Aisen, P. S. S., Petersen, R. C., Jack, C. R., Jagust, W. J., Trojanowki, J. Q., Toga, A. W., Beckett, L., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.18479 · Cited by 38
Self-citationYu, M., Risacher, S. L., Nho, K. T., Wen, Q., Oblak, A. L., Unverzagt, F. W., Apostolova, L. G., Farlow, M. R., Brosch, J. R., Clark, D. G., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113691 · Cited by 36
Shi, Y., Zeng, W., Deng, J., Nie, W., & Zhang, Y. (2020) · IEEE Journal of Translational Engineering in Health and Medicine · doi:10.1109/jtehm.2020.2985022 · Cited by 34
PET Image Deblurring and Super-Resolution With an MR-Based Joint Entropy Prior
Song, T.-A., Yang, F., Chowdhury, S. R., Kim, K., Johnson, K. A., Fakhri, G. E., Li, Q., & Dutta, J. (2019) · IEEE Transactions on Computational Imaging · doi:10.1109/tci.2019.2913287 · Cited by 33
Cervenka, S., Frick, A., Bodén, R., & Lubberink, M. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01990-2 · Cited by 32
Beckman, D., Diniz, G. B., Ott, S. P., Hobson, B. A., Chaudhari, A. J., Muller, S., Chu, Y., Takano, A., Schwarz, A. J., Yeh, C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13868 · Cited by 32
Timmers, T., Ossenkoppele, R., Visser, D., Tuncel, H., Wolters, E. E., Verfaillie, S. C. J., van der Flier, W. M., Boellaard, R., Golla, S. S. V., & van Berckel, B. N. M. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19879226 · Cited by 32
Manipulation of the diet–microbiota–brain axis in Alzheimer’s disease
Lee, D. D., Lee, V. M. ‐., & Hur, S. K. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1042865 · Cited by 27
Identification of late-stage tau accumulation using plasma phospho-tau217
Woo, M. S., Therriault, J., Jonaitis, E. M., Wilson, R. E., Langhough, R. E., Rahmouni, N., Benedet, A. L., Ashton, N. J., Tissot, C., Lantero‐Rodriguez, J., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105413 · Cited by 34
Phillips, J. S., Nitchie, F. J., Re, F. D., Olm, C. A., Cook, P. A., McMillan, C. T., Irwin, D. J., Gee, J. C., Dubroff, J. G., Grossman, M., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12456 · Cited by 33
Alzheimer Disease Pathology and Neurodegeneration in Midlife Obesity: A Pilot Study
Dolatshahi, M., Commean, P. K., Rahmani, F., Liu, J., Lloyd, L., Nguyen, C., Hantler, N., Ly, M. J., Yu, G. Z., Ippolito, J. E., et al. (2023) · Aging and Disease · doi:10.14336/ad.2023.0707 · Cited by 31
Lantero‐Rodriguez, J., Tissot, C., Snellman, A., Servaes, S., Benedet, A. L., Rahmouni, N., Montoliu‐Gaya, L., Therriault, J., Brum, W. S., Stevenson, J., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13119 · Cited by 30
Biel, D., Luan, Y., Brendel, M., Hager, P., Dewenter, A., Moscoso, A., Svaldi, D. O., Higgins, I. A., Pontecorvo, M. J., Roemer, S. N., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01105-5 · Cited by 34
Park, D. C., Hennessee, J. P., Smith, E. T., Chan, M. Y., Chen, X., Dakanali, M., Farrell, M. E., Liu, P., Lu, H., Rofsky, N., et al. (2025) · Scientific Data · doi:10.1038/s41597-025-04847-7 · Cited by 38
Tissot, C., Servaes, S., Lussier, F. Z., Ferrari‐Souza, J. P., Therriault, J., Ferreira, P. C. L., Bezgin, G., Bellaver, B., Leffa, D. T., Mathotaarachchi, S. S., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264434 · Cited by 30
Burnham, S. C., Iaccarino, L., Pontecorvo, M. J., Fleisher, A., Lu, M., Collins, E. C., & Devous, M. D. (2023) · Brain Communications · doi:10.1093/braincomms/fcad305 · Cited by 30
Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?
Merighi, S., Poloni, T. E., Terrazzan, A., Moretti, E., Gessi, S., & Ferrari, D. (2021) · Cells · doi:10.3390/cells10051267 · Cited by 30
Llibre-Guerra, J. J., Fernandez, M. V., Joseph-Mathurin, N., Bian, S., Carter, K., Li, Y., Aschenbrenner, A. J., Pottier, C., Sigurdson, W., McDade, E., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03494-0 · Cited by 28
Synthesizing images of tau pathology from cross-modal neuroimaging using deep learning
Lee, J., Burkett, B. J., Min, H.-K. P., Senjem, M. L., Dicks, E., Corriveau‐Lecavalier, N., Mester, C. T., Wiste, H. J., Lundt, E. S., Murray, M. E., et al. (2023) · Brain · doi:10.1093/brain/awad346 · Cited by 32
Self-citationAdvances in Modeling Alzheimer's Disease In Vitro
Sharma, N. S., Karan, A., Lee, D.-H., Yan, Z., & Xie, J. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100097 · Cited by 31
Ferreira, P. C. L., Ferrari‐Souza, J. P., Tissot, C., Bellaver, B., Leffa, D. T., Lussier, F. Z., Povala, G., Therriault, J., Benedet, A. L., Ashton, N. J., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207115 · Cited by 28
VandeVrede, L. A., Joie, R. L., Horiki, S., Mundada, N. S., KOESTLER, M. E., Hwang, J., Ljubenkov, P. A., Rojas, J. C., Rabinovici, G. D., Boxer, A. L., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02631-8 · Cited by 28
Comparison of cerebrospinal fluid, plasma and neuroimaging biomarker utility in Alzheimer’s disease
Meeker, K. L., Luckett, P. H., Barthélemy, N. R., Hobbs, D. A., Chen, C. D., Bollinger, J., Ovod, V., Flores, S. E., Keefe, S., Henson, R. L., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae081 · Cited by 30
Serum FOXO3A: A ray of hope for early diagnosis of Alzheimer’s disease
Pradhan, R., Yadav, S. K., Prem, N. N., Bhagel, V., Pathak, M., Shekhar, S., Gaikwad, S., Dwivedi, S. N., Bal, C. S., Dey, A. B., et al. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111290 · Cited by 26
Seo, E. H., Lim, H. J., Yoon, H., Choi, K. Y., Lee, J. J., Park, J. Y., Choi, S. H., Kim, H., Kim, B. C., & Lee, K. H. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00909-1 · Cited by 26
β-Amyloid and Tau Imaging in Chronic Traumatic Brain Injury
Hicks, A. J., Ponsford, J. L., Spitz, G., Doré, V., Krishnadas, N., ROBERTS, C. M., & Rowe, C. C. (2022) · Neurology · doi:10.1212/wnl.0000000000200857 · Cited by 26
Implication of tau propagation on neurodegeneration in Alzheimer’s disease
Lamontagne-Kam, D., Ulfat, A. K., Hervé, V., Vu, T.-M., & Brouillette, J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1219299 · Cited by 28
Predicting functional decline in aging and Alzheimer’s disease with PET-based Braak staging
Macedo, A. C., Therriault, J., Tissot, C., Arias, J. F., Ferreira, P. C. L., Vitali, P., Servaes, S., Rahmouni, N., Vermeiren, M. R., Bezgin, G., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae043 · Cited by 24
Krishnadas, N., Doré, V., Lamb, F., Groot, C., McCrory, P. R., Guzman, R., Mulligan, R. S., Huang, K., O'Donnell, M. L., Ponsford, J. L., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.598980 · Cited by 25
TauIQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans
Whittington, A., Gunn, R. N., & Initiative, A. D. N. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.258962 · Cited by 24
Alzheimer's disease diagnostic accuracy by fluid and neuroimaging ATN framework
Xiong, X., He, H., Ye, Q., Qian, S., Zhou, S., Feng, F., Fang, E. F., & Xie, C. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14357 · Cited by 24
Rankovic, M., & Zweckstetter, M. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.12.014 · Cited by 25
Perani, D., Iaccarino, L., Lammertsma, A. A., Windhorst, A. D., Edison, P., Boellaard, R., Hansson, O., Nordberg, A. K., Jacobs, A. H., & IMBI Project (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.02.004 · Cited by 25
McGeachan, R. I., Meftah, S., Taylor, L. W., Catterson, J. H., Negro, D., Bonthron, C., Holt, K., Tulloch, J., Rose, J. L., Gobbo, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58879-z · Cited by 23
Variants inPPP2R2BandIGF2BP3are associated with higher tau deposition
Ramanan, V. K., Wang, X., Przybelski, S. A., Raghavan, S., Heckman, M. G., Batzler, A. J., Kosel, M., Hohman, T. J., Knopman, D. S., Graff‐Radford, J., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa159 · Cited by 23
Self-citationCampese, N., Palermo, G., Gamba, C. D., Beatino, M. F., Galgani, A., Belli, E., Prete, E. D., Vecchia, A. D., Vergallo, A., Siciliano, G., et al. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1886929 · Cited by 23
Cerebrospinal fluid and blood biomarkers in the diagnostic assays of Alzheimer’s disease
Zhang, L., Liang, X., Zhang, Z., & Luo, H. (2021) · Journal of Innovative Optical Health Sciences · doi:10.1142/s1793545822300014 · Cited by 24
Kotari, V., Southekal, S. S., Navitsky, M. A., Kennedy, I. A., Lu, M., Morris, A., Zimmer, J. A., Fleisher, A., Mintun, M. A., Devous, M. D., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01160-6 · Cited by 25
Malpas, C. B., Sharmin, S., & Kalinčík, T. (2020) · International Journal of Neuroscience · doi:10.1080/00207454.2020.1758087 · Cited by 25
Finding specificity in structural brain alterations through Bayesian reverse inference
Cauda, F., Nani, A., Liloia, D., Manuello, J., Premi, E., Duca, S., Fox, P. T., & Costa, T. (2020) · Human Brain Mapping · doi:10.1002/hbm.25105 · Cited by 24
Metadata
- Authors
- Jack, C. R., Wiste, H. J., Schwarz, C. G., Lowe, V. J., Senjem, M. L., Vemuri, P., Weigand, S. D., Therneau, T. M., Knopman, D. S., Gunter, J. L., Jones, D. T., Graff-Radford, J., Kantarci, K., Roberts, R. O., Mielke, M. M., Machulda, M. M., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
- Corresponding author
- Jack, Clifford R
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-03-12
- Volume
- 141
- Issue
- 5
- Pages
- 1517-1528
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC5917767
- OpenAlex
- W2791135917
- Cited by
- 452
- References
- 54
- Citations by year
- 2026: 36 · 2025: 56 · 2024: 61 · 2023: 49 · 2022: 55 · 2021: 75 · 2020: 56 · 2019: 46 · 2018: 18
- FWCI
- 37.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- NIH (R01 AG011378, R01 AG041851, U01 AG006786, R01 AG034676, R01 NS097495, P50 AG016574)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- tau PET, Alzheimer's disease, amyloid PET, within-person change, sample size determination, clinical trial outcome measures, amyloid-beta, entorhinal cortex, temporal lobe, cognitive impairment, cortical volume, memory decline, brain atrophy
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alzheimer Disease, Brain, Female, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Psychiatric Status Rating Scales, tau Proteins, Positron-Emission Tomography, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
